EUVIMEDEUVIMED entdecken
Crossref

Long-Term Findings of N-Acetyl-L-leucine for Niemann–Pick Disease Type C

K. Martakis, A. Hahn, T. Fields, M. Strupp, T. Bremova-Ertl

Neuropediatrics · 01.10.2024 · 55 (S 01 S 01) · S1-S25

DOI: 10.1055/s-0044-1791909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropediatrics, erschienen am 01.10.2024. Verfasst von K. Martakis und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Purpose: The IB1001-301 clinical trial was a Phase III, double-blind, randomized, placebo-controlled trial comparing N -acetyl-L-leucine (NALL) with placebo for the treatment of neurological signs and symptoms in children and adults with Niemann–Pick disease type C (NPC) after a treatment period of 12 weeks. The primary Scale for the Assessment and Rating of Ataxia (SARA) endpoint was reduced −1.97 points with NALL and −0.60 with placebo ( p < 0.001). Extended follow-up data were obtained in an open-label Extension Phase (EP) to evaluate the long-term, neuroprotective effects of NALL for NPC.

Methods

Patients received treatment with orally administered NALL 2 to 3 times per day in tiers of weight-based dosing. The primary endpoint was the modified 5-domain NPC Clinical Severity Scale (5-Domain NPC-CSS) (range 0–25 points; lower score representing better neurological status). Comparisons were made to the expected annual trajectory of disease decline established in published natural history studies. Exploratory endpoints included the 17-domain NPC-CSS (excluding hearing) and SARA.

Results

A total of 54 patients aged 5 to 67 years were treated in the EP. After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.115 (±2.60) and 1.5 ± 3.1 in the historical cohort (mean difference 1.56; 95% confidence interval, 0.31–2.92; p < 0.017), a 108% reduction in annual disease progression. The result of the 17-domain NPC-CSS (excluding hearing) was supportive of the primary analysis and the improvements in neurological status demonstrated in the Parent Study’s primary SARA endpoint were sustained over the long-term follow-up. NALL was well-tolerated, and no treatment-related serious AEs occurred.

Conclusion

Children and adults with NPC who were treated with NALL after 1 year showed a statistically and clinically significant reduction in disease progression, consistent with a neuroprotective and disease-modifying effect. Publication History Article published online: 08 October 2024 Georg Thieme Verlag KG Stuttgart · New York

Zitieren

APA

Martakis, K., Hahn, A., Fields, T., Strupp, M., & Bremova-Ertl, T. (2024). Long-Term Findings of N-Acetyl-L-leucine for Niemann–Pick Disease Type C. Neuropediatrics, 55(S 01 S 01), S1-S25. https://doi.org/10.1055/s-0044-1791909

Vancouver

Martakis K, Hahn A, Fields T, Strupp M, Bremova-Ertl T. Long-Term Findings of N-Acetyl-L-leucine for Niemann–Pick Disease Type C. Neuropediatrics. 2024;55(S 01 S 01):S1-S25. doi:10.1055/s-0044-1791909

BibTeX
@article{Martakis2024,
  author = {Martakis, K. and Hahn, A. and Fields, T. and Strupp, M. and Bremova-Ertl, T.},
  title = {Long-Term Findings of N-Acetyl-L-leucine for Niemann–Pick Disease Type C},
  journal = {Neuropediatrics},
  year = {2024},
  volume = {55},
  number = {S 01 S 01},
  pages = {S1--S25},
  doi = {10.1055/s-0044-1791909}
}
Kostenlos starten →